Acquired Company

Selecta Biosciences acquired Cartesian Therapeutics, Inc. on 11/14/2023 in a stock-for-stock merger, with the combined company renamed Cartesian Therapeutics, Inc. and its common stock trading under RNAC.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland. Show more

7495 New Horizon Way, Frederick, MD, 21703, United States

https://www.cartesiantherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

181.5M

52 Wk Range

$5.98 - $19.50

Previous Close

$6.98

Open

$7.02

Volume

296,306

Day Range

$6.91 - $7.75

Enterprise Value

121.9M

Cash

143.4M

Avg Qtr Burn

-15.6M

Insider Ownership

60.76%

Institutional Own.

20.03%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SEL-212 (Pegadricase) Details Chronic refractory gout, Arthritis	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Myasthenia gravis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Myositis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Juvenile dermatomyositis, Juvenile systemic lupus erythematosus (SLE), Juvenile Myasthenia gravis (MG), Anti-neutrophil cytoplasmic antibody associated vasculitis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-15 Details Multiple myeloma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Systemic lupus erythematosus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SEL-302 (MMA-101 + ImmTOR) Details Genetic disorder, Methylmalonic acidemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.